ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 9.190-9.690 for the period, compared to the consensus estimate of 9.100. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

ANI Pharmaceuticals Stock Down 5.3%

ANIP traded down $4.38 on Friday, hitting $78.25. 1,019,908 shares of the company were exchanged, compared to its average volume of 379,509. ANI Pharmaceuticals has a 12 month low of $70.15 and a 12 month high of $99.50. The company has a market cap of $1.78 billion, a PE ratio of 19.81 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The stock’s fifty day moving average is $81.03 and its 200-day moving average is $79.38.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the previous year, the firm earned $1.80 EPS. The business’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts predict that ANI Pharmaceuticals will post 8.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Guggenheim reaffirmed a “buy” rating and set a $124.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group began coverage on ANI Pharmaceuticals in a report on Thursday, July 16th. They set a “hold” rating and a $91.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.00.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 3,313 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total value of $284,918.00. Following the transaction, the chief financial officer directly owned 177,543 shares of the company’s stock, valued at $15,268,698. This trade represents a 1.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the sale, the director directly owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This trade represents a 20.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 88,029 shares of company stock worth $6,954,472. Corporate insiders own 8.10% of the company’s stock.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.21, exceeding the roughly $2.01-$2.04 consensus range, while revenue of $266.0 million surpassed estimates near $260 million. Revenue increased 25.9% year over year, and adjusted EBITDA rose 32.4% to $71.6 million. ANI Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Purified Cortrophin Gel revenue climbed 43.5% to $117.1 million. Management said the expansion into podiatrists and primary-care physicians for acute gout was fully operational by June, with encouraging early prescribing and patient-case trends. ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
• Positive Sentiment: ANI reaffirmed full-year 2026 revenue guidance of $1.08 billion-$1.14 billion, adjusted EBITDA of $285 million-$300 million and adjusted EPS of $9.19-$9.69, above the prior consensus EPS estimate of $9.10. The company also has authorization for up to $100 million in share repurchases through May 2029. ANI Pharmaceuticals Reports Second-Quarter 2026 Results
• Neutral Sentiment: Generics revenue increased 9.7% to $99.1 million, supported by new launches, while ANI reported 12 generic launches year to date and remains on track for at least 15 in 2026.
• Negative Sentiment: ANI reduced its 2026 Cortrophin Gel revenue target to $520 million-$540 million from $540 million-$575 million. Although the revised range still implies 50%-55% growth, the cut may have disappointed investors expecting stronger near-term performance.
• Negative Sentiment: Gross margin fell to 62.4% from 64.7%, partly because of a greater mix of royalty-bearing products. Selling, general and administrative costs rose 12.1% as ANI expanded its rare-disease sales force for the gout opportunity.
• Negative Sentiment: ILUVIEN revenue declined 16.1% to $18.7 million because of international shipment timing, while Brands revenue fell 10.5% amid normalized demand.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently modified their holdings of ANIP. Invesco Ltd. boosted its position in shares of ANI Pharmaceuticals by 26.0% during the 4th quarter. Invesco Ltd. now owns 189,836 shares of the specialty pharmaceutical company’s stock valued at $14,986,000 after purchasing an additional 39,178 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $1,243,000. Susquehanna Portfolio Strategies LLC bought a new position in shares of ANI Pharmaceuticals during the 4th quarter worth about $906,000. Tang Capital Management LLC increased its position in ANI Pharmaceuticals by 51.6% in the 4th quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after buying an additional 163,937 shares in the last quarter. Finally, Twinbeech Capital LP bought a new position in ANI Pharmaceuticals in the fourth quarter worth approximately $276,000. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.